Randomized phase III trial of temsirolimus versus sorafenib as second-line therapy after sunitinib in patients with metastatic renal cell carcinoma. - Wikidata - awgldk - TriplyDB

Randomized phase III trial of temsirolimus versus sorafenib as second-line therapy after sunitinib in patients with metastatic renal cell carcinoma.

Randomized phase III trial of temsirolimus versus sorafenib as second-line therapy after sunitinib in patients with metastatic renal cell carcinoma.

http://www.wikidata.org/entity/Q34658095

about

Contemporary Treatment of Metastatic Renal Cell Carcinoma Axitinib in the treatment of renal cell carcinoma: patient selection and perspectives Beyond evidence-based data: scientific rationale and tumor behavior to drive sequential and personalized therapeutic strategies for the treatment of metastatic renal cell carcinoma Chinese guidelines on the management of renal cell carcinoma (2015 edition)Sequence of treatment in locally advanced and metastatic renal cell carcinoma Current management and future directions in the treatment of advanced renal cell carcinoma-a latin american perspective: 10 years in review Clinical experience with everolimus in the second-line treatment of advanced renal cell carcinoma Clinical use of cabozantinib in the treatment of advanced kidney cancer: efficacy, safety, and patient selection Endothelial Cell mTOR Complex-2 Regulates Sprouting Angiogenesis Efficacy and Safety of Sorafenib Therapy on Metastatic Renal Cell Carcinoma in Korean Patients: Results from a Retrospective Multicenter Study Renal cell cancer: overview of the current therapeutic landscape.Phase I trial of sunitinib and temsirolimus in metastatic renal cell carcinoma.Axitinib versus sorafenib in advanced renal cell carcinoma: subanalyses by prior therapy from a randomised phase III trial Correlation of genomic alterations assessed by next-generation sequencing (NGS) of tumor tissue DNA and circulating tumor DNA (ctDNA) in metastatic renal cell carcinoma (mRCC): potential clinical implications Implementation of an Interleukin-2 National Registry: an opportunity to improve cancer outcomes Risk of treatment-related deaths with vascular endothelial growth factor receptor tyrosine kinase inhibitors: a meta-analysis of 41 randomized controlled trials.Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma SEOM clinical guidelines for the treatment of renal cell carcinoma.Immunologics and chemotherapeutics for renal cell carcinoma.Targeted treatments in advanced renal cell carcinoma: focus on axitinib.Optimal first-line and second-line treatments for metastatic renal cell carcinoma: current evidence.Comparative Effectiveness of Second-Line Targeted Therapies for Metastatic Renal Cell Carcinoma: A Systematic Review and Meta-Analysis of Real-World Observational Studies Evaluation of second-line and subsequent targeted therapies in metastatic renal cell cancer (mRCC) patients treated with first-line cediranib.Everolimus in metastatic renal cell carcinoma after failure of initial anti-VEGF therapy: final results of a noninterventional study.A systematic review of the efficacy and safety experience reported for sorafenib in advanced renal cell carcinoma (RCC) in the post-approval setting.Comparing comparators: a look at control arms in kidney cancer studies over the years.Sunitinib re-challenge in advanced renal-cell carcinoma.Risk of treatment-related mortality with sorafenib in cancer patients: a meta-analysis of 20 randomly controlled trials : Risk of sorafenib-associated death.SOX9 was involved in TKIs resistance in renal cell carcinoma via Raf/MEK/ERK signaling pathway.Clinical experience with temsirolimus in the treatment of advanced renal cell carcinoma Increased risk of severe infections in cancer patients treated with vascular endothelial growth factor receptor tyrosine kinase inhibitors: a meta-analysis Angiotensin system inhibitors and survival outcomes in patients with metastatic renal cell carcinoma.A retrospective study of predictive factors for unexpectedly prolonged or shortened progression-free survival and overall survival among patients with metastatic renal cell carcinoma who received first-line targeted therapy Potential impact of mTOR inhibitors on cervical squamous cell carcinoma: A systematic review.Sorafenib versus sunitinib as first-line treatment agents in Chinese patients with metastatic renal cell carcinoma: the largest multicenter retrospective analysis of survival and prognostic factors.Efficacy of sequential therapies with sorafenib-sunitinib versus sunitinib-sorafenib in metastatic renal cell carcinoma: A systematic review and meta-analysis.Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial BEZ235: When Promising Science Meets Clinical Reality Axitinib after Sunitinib in Metastatic Renal Cancer: Preliminary Results from Italian "Real-World" SAX Study.Efficacy and Toxicity of Mammalian Target Rapamycin Inhibitors in Patients with Metastatic Renal Cell Carcinoma with Renal Insufficiency: The Korean Cancer Study Group GU 14-08.

P2860

Q26740594-41569147-3289-409D-B42D-3C7158886A7B Q26751341-E766183E-F125-4E15-B42D-93E2F3AA3BB4 Q26766240-3B450D5B-D00C-4A7E-81A9-04F764114E11 Q26772206-9B802659-3E22-41CA-8947-B9067ABEA063 Q26773653-FC3D8A5B-E952-4AF1-8EBF-BA17E3169A08 Q26774515-E0045688-1960-43C9-93CD-D1D1D88F5BC2 Q26783514-9E519B6B-F560-4ADE-A2C7-0B6FD2294AF7 Q28074834-6A35D4DA-15FC-47D4-AB8D-5FE312611161 Q28547399-8D41EE06-FFD1-4ECC-8601-2E0C2694CFD6 Q28547506-8001F25F-1D86-4AE0-B9BE-4EED2B88A15B Q30248354-B2184E29-59AA-4AF7-B1E8-07395E85207A Q33419097-705986F8-0A25-47A1-9896-936B14DAA39A Q33750154-301C75A9-D49E-461A-83B9-A97C2D6F90E5 Q33779585-5048C6FC-1BE1-48F9-A03D-50781F48588A Q33909119-4595F5A0-5811-480F-A74C-DE9AE5EC7304 Q34352627-E0A6A8FD-D8E6-4EB3-933D-26AFBF42A705 Q34495684-8262FDCA-BE3B-4766-B3B1-E2D86AE90013 Q34553411-00E6FBEB-9226-4075-AFD5-62FAD62CD58D Q34660154-BD633179-1710-4272-9C87-3D594C7E74EF Q34661185-E1C74838-F481-46BF-AE6B-B354F9C38CCE Q34666150-0A85E768-D0FD-460D-87DC-EB251E4C6E58 Q34672506-EB0A35B1-D5F0-4385-B20C-EAE67F5F2D68 Q34777424-6C82993A-358F-4E81-90B6-91EED5D6EB11 Q35549876-131B7F06-D4B5-4F78-8CAD-A749B3CA3958 Q35591889-3C06E8CD-F970-43CA-ABA9-AB620002208D Q35677657-2D023375-3182-4D67-9343-9E09EE57E8AB Q35678358-48512B26-324D-43F2-A498-0C211FEEC5D6 Q35691234-BC1354FF-56FF-4468-98E6-A46867B9A66D Q35741056-41E736DE-1337-4483-A479-64C241AAB16B Q35797388-8B2F9CBC-D263-4FF5-9E81-48B96F7EAC5A Q36024704-C5C8122F-8C09-4902-99DA-29EF7A861BE5 Q36051199-BD1A0F05-3D54-4C0B-8745-41F5E148543A Q36092829-3BDEC902-5876-4911-A1F6-DCA6821F9AF6 Q36206239-0AE2B43B-18C3-4F49-97E5-1E48EBD5A381 Q36241010-337B4556-1612-4E87-A4F1-3C6F385667A7 Q36252946-EBBD5C40-D7F1-4006-8F5A-226609834C29 Q36726204-D54804AB-D770-453B-A718-85040768BFA0 Q37242369-0427872C-3348-4480-B6FD-40F195A30762 Q37290050-BEC6A71E-4286-4183-9DC7-D574C92EC6E0 Q37367458-D3633544-E63B-4C3D-B55C-3847CF6C5781

P2860

Randomized phase III trial of temsirolimus versus sorafenib as second-line therapy after sunitinib in patients with metastatic renal cell carcinoma.

http://www.wikidata.org/entity/Q34658095

description

2013 nî lūn-bûn

@nan

2013 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

Randomized phase III trial of ...... tastatic renal cell carcinoma.

@ast

Randomized phase III trial of ...... tastatic renal cell carcinoma.

@en

Randomized phase III trial of ...... tastatic renal cell carcinoma.

@nl

type

label

Randomized phase III trial of ...... tastatic renal cell carcinoma.

@ast

Randomized phase III trial of ...... tastatic renal cell carcinoma.

@en

Randomized phase III trial of ...... tastatic renal cell carcinoma.

@nl

prefLabel

Randomized phase III trial of ...... tastatic renal cell carcinoma.

@ast

Randomized phase III trial of ...... tastatic renal cell carcinoma.

@en

Randomized phase III trial of ...... tastatic renal cell carcinoma.

@nl

P1433

Q34658095-B7776649-CE13-4CE4-AD3F-DC2B7865F076

P1476

Q34658095-91CF7F8E-018F-4477-ADB9-889D89950FE9

P2093

Q34658095-117FDB27-D7C6-476A-BD71-1EE4A50DB4F4

Q34658095-3855DA15-5744-45FA-B6B3-A917B2CFABB2

Q34658095-3C61743A-EC66-42E6-891A-BA3D17BE1A1F

Q34658095-43BEE17E-0311-4F10-BB91-3251A01A1048

Q34658095-94866EDC-D4E6-4645-92F4-34E790B73DE2

Q34658095-9C125CE9-5DB9-4BD4-8365-1703C876902A

Q34658095-CD116940-045F-46DF-BA8D-3F630A6E5799

Q34658095-FF4D2D75-F696-42BE-8F68-B66F0D03C260

P2860

Q34658095-0635C340-8B7C-41A9-B942-7E24068F3D48

Q34658095-1B1E04C3-FCC3-4F49-8EDD-6E6AD0185B8C

Q34658095-2672B7F9-36B5-4DF4-8D0C-C23DF6E98625

Q34658095-3517D44D-42F0-4A89-8AB2-A2B73258AC47

Q34658095-38E8B476-8DAE-4F78-9A8D-87DBB0BED222

Q34658095-3CA32498-9B4F-4740-B9D2-8F2E66A9AD1E

Q34658095-475AB177-44FD-459F-A03A-F92A70B2CE36

Q34658095-4931CFB3-F856-40E0-BA21-B0BD9E61B29D

Q34658095-5AC119EF-C158-418D-A6B4-2D92E403FEEF

Q34658095-71CC7D91-E81A-43D3-A505-C594ED487DAA

P304

Q34658095-2F3F8AB1-DF0D-4832-BF61-715D912E9AC7

P31

Q34658095-D36A6CBE-A5B6-467E-B00D-5B4716D6F292

P356

Q34658095-3155E3F9-600D-4A3F-A065-87C4C25321AC

P407

Q34658095-292241A7-2FBF-4E1F-8C09-9C90066CDD6D

P433

Q34658095-36182035-8DE9-4900-8181-92D4962DEF3D

P478

Q34658095-D317AE53-639F-44C6-B9DC-8FB7C811530F

P50

Q34658095-6D046699-4E54-44B5-AA9E-0218FF2E4601

Q34658095-EAE05081-A50C-4E0C-B143-803C52105020

Q34658095-ED748B48-BF48-4469-B9FA-883801829206

P577

Q34658095-A1C54786-19A1-4638-9196-78D1A8EE00F7

P698

Q34658095-418C5DFC-6319-4406-A070-B38928678EAE

P921

Q34658095-3027E7FD-2CB8-4B93-AD3A-475A1725116A

P932

Q34658095-7108EC52-7160-4C42-BE24-13A6FEBB122C

P356

JCO.2013.50.3961

P1433

Journal of Clinical Oncology

P1476

Randomized phase III trial of ...... etastatic renal cell carcinoma

@en

P2093

Andreas Niethammer

http://www.w3.org/2001/XMLSchema#string

Bernard Escudier

http://www.w3.org/2001/XMLSchema#string

Dongrui Ray Lu

http://www.w3.org/2001/XMLSchema#string

Ho Yeong Lim

http://www.w3.org/2001/XMLSchema#string

Kenneth B Pittman

http://www.w3.org/2001/XMLSchema#string

Peggy Senico

http://www.w3.org/2001/XMLSchema#string

Subramanian Hariharan

http://www.w3.org/2001/XMLSchema#string

Thomas E Hutson

http://www.w3.org/2001/XMLSchema#string

P2860

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma

Sorafenib in advanced clear-cell renal-cell carcinoma

Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial

Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial

Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma

Primary anti-vascular endothelial growth factor (VEGF)-refractory metastatic renal cell carcinoma: clinical characteristics, risk factors, and subsequent therapy

Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial.

Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial.

P304

760-767

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JCO.2013.50.3961

http://www.w3.org/2001/XMLSchema#string

P407

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

32

http://www.w3.org/2001/XMLSchema#string

P50

Georg A. Bjarnason

P577

2013-12-02T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24297950

http://www.w3.org/2001/XMLSchema#string

P921

phase III clinical trial

P932

5569683

http://www.w3.org/2001/XMLSchema#string